Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE)

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Pfizer
• Treatments: Apixaban; Enoxaparin; Enoxaparin sodium; Warfarin

Criteria

Inclusion Criteria:

• Men and women ≥ 18 years of age

• Clinical diagnosis of DVT or PE

Exclusion Criteria:

• Contraindications for enoxaparin or warfarin

• Active bleeding or high risk for serious bleeding

• Short life expectancy

• Uncontrolled high blood pressure

• Significantly impaired kidney or liver function